Items where Subject is "RS Pharmacy and materia medica"

Library of Congress subjects (102130) R Medicine (9801) RS Pharmacy and materia medica (239)
Number of items at this level: 239.
Article
  • The Community Pharmacy Medicines Management Project Evaluation Team (2008). Evaluation of medication reviews conducted by community pharmacists: a quantitative analysis of documented issues and recommendations. British Journal of Clinical Pharmacology, 65(3), 386-396. https://doi.org/10.1111/j.1365-2125.2007.03022.x
  • Community Pharmacy Medicines Management Team (2008). Patients’ experiences of a community pharmacy-led medicines management service. Health and Social Care in the Community, 16(4), 363-369. https://doi.org/10.1111/j.1365-2524.2007.00749.x
  • Scientific Programme Committee of the 2015 PPRI Conference (2016). Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 9(9). https://doi.org/10.1186/s40545-016-0056-8
  • Agosto, Arianna, Cerchiello, Paola, Eisenberg, Siegfried, Czypionka, Thomas (2025). European countries policy responses against SARS-Cov-2 in the context of vaccinations. Scientific Reports, 15(1). https://doi.org/10.1038/s41598-025-11881-3 picture_as_pdf
  • Anderson, Michael, Naci, Huseyin, Morrison, Deborah, Osipenko, Leeza, Mossialos, Elias (2018). A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology, https://doi.org/10.1016/j.jclinepi.2018.09.003
  • Angelis, Aris (2018). Evaluating the benefits of new drugs in health technology assessment using multiple criteria decision analysis: a case study on metastatic prostate cancer with the dental and pharmaceuticals benefits agency (TLV) in Sweden. MDM: Policy and Practice, 3(2). https://doi.org/10.1177/2381468318796218
  • Angelis, Aris, Kanavos, Panos (2017). Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the Advance Value Framework. Social Science & Medicine, 188, 137-156. https://doi.org/10.1016/j.socscimed.2017.06.024
  • Angelis, Aris, Phillips, Lawrence D. (2021). Advancing structured decision-making in drug regulation at the FDA and EMA. British Journal of Clinical Pharmacology, 87(2), 395 - 405. https://doi.org/10.1111/bcp.14425 picture_as_pdf
  • Athanasakis, Kostas, Kyriopoulos, Ilias, Kyriopoulos, John (2018). To switch or not to switch? Patient attitudes towards generic substitution in Greece. Journal of Pharmaceutical Health Services Research, 9(3), 271-273. https://doi.org/10.1111/jphs.12246
  • Bakker, Gerben (2010). Book review: Wellcome & co.: knowledge, trust, profit and the transformation of the British pharmaceutical industry, 1880-1940. Medical History, 54(2), 260-261. https://doi.org/10.1017/S0025727300006773
  • Banerjee, Sube, Hellier, J, Romer, R, Dewey, M, Knapp, Martin, Ballard, C, Baldwin, Robert, Bentham, Peter, Fox, C. & Holmes, Clive et al (2013). Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technology Assessment, 17(7). https://doi.org/10.3310/hta17070
  • Bergsma, W. P., Aris, E. M. D., Tibaldi, F. S. (2013). Linear Categorical Marginal Modeling of solicited symptoms in vaccine clinical trials. Statistics in Biopharmaceutical Research, 5(1), 27-37. https://doi.org/10.1080/10496491.2012.738111
  • Bogacka, Barbara, Patan, Maciej, Johnson, Patrick, J, Youdim, K, Atkinson, Anthony C. (2011). Optimum design of experiments for enzyme inhibition kinetic models. Journal of Biopharmaceutical Statistics, 21(3), 555-572. https://doi.org/10.1080/10543406.2010.489979
  • Bradley, James, Vandoros, Sotiris (2012). Creative compliance in pharmaceutical markets: the case of profit controls. Expert Review of Pharmacoeconomics and Outcomes Research, 12(1), 31-38. https://doi.org/10.1586/erp.11.86
  • Cerri, Karin H., Knapp, Martin, Fernandez, Jose-Luis (2013). Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making. European Journal of Health Economics, 15(7), 681-695. https://doi.org/10.1007/s10198-013-0514-z
  • Civitelli, Diego, Mills, Mackenzie, Kanavos, Panos (2025). HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments. Value in Health, 28(6, Supplement 1), S259. https://doi.org/10.1016/j.jval.2025.04.1080
  • Cornford, Tony, Savage, Imogen, Jani, Yogini, Franklin, Bryony Dean, Barber, Nick, Slee, Ann, Jacklin, Ann (2010). Learning lessons from electronic prescribing implementations in secondary care. Studies in Health Technology and Informatics, 160, 233-237. https://doi.org/10.3233/978-1-60750-588-4-233
  • Costa-Font, Joan (2016). Deregulation and access to medicines: the Peruvian experience. Journal of International Development, 28(6), 997-1005. https://doi.org/10.1002/jid.3096
  • Costa-Font, Joan, McGuire, Alistair, Varol, Nebibe (2015). Regulation effects on the adoption of new medicines. Empirical Economics, 49(3), 1101-1121. https://doi.org/10.1007/s00181-014-0903-x
  • Crea, Giovanni, Galizzi, Matteo M., Linnosmaa, Ismo, Miraldo, Marisa (2019). Physician altruism and moral hazard: (no) evidence from Finnish national prescriptions data. Journal of Health Economics, 65, 153-169. https://doi.org/10.1016/j.jhealeco.2019.03.006 picture_as_pdf
  • Ferrario, Alessandra, Kanavos, Panos (2015). Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Social Science & Medicine, 124, 39-47. https://doi.org/10.1016/j.socscimed.2014.11.003 picture_as_pdf
  • Ferrario, Alessandra, Sautenkova, Nina, Bezverhni, Zinaida, Seicas, Rita, Habicht, Jarno, Kanavos, Panos, Safta, Vladimir (2014). An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of Pharmaceutical Policy and Practice, 7(1), p. 4. https://doi.org/10.1186/2052-3211-7-4
  • Gandecha, Reshma, Klecun, Ela, Jacklin, Ann, Williams, Simon (2005). What the national IT programme means for pharmacy and pharmacists. Pharmaceutical Journal, 275(7357), 56-60.
  • Gerard, Karen, Tinelli, Michela, Latter, Sue, Blenkinsopp, Alison, Smith, Alesha (2012). Valuing the extended role of prescribing pharmacist in general practice: results from a discrete choice experiment. Value in Health, 15(5), 699-707. https://doi.org/10.1016/j.jval.2012.02.006
  • Gurgula, Olga, McDonagh, Luke (2025). On compulsory licensing of trade secrets to safeguard public health. Cambridge Law Journal, 1 - 34. https://doi.org/10.1017/s0008197325100998 picture_as_pdf
  • Heims, Eva, Moxon, Sophie (2024). Mechanisms of regulatory capture: testing claims of industry influence in the case of Vioxx. Regulation and Governance, 18(1), 139-157. https://doi.org/10.1111/rego.12531 picture_as_pdf
  • Hernandez, Inmaculada, Cousin, Emma, Wouters, Olivier J., Gabriel, Nico, Cameron, Teresa, Sullivan, Sean D. (2024). Medicare drug price negotiation: the complexities of selecting therapeutic alternatives for estimating comparative effectiveness. Journal of Managed Care & Specialty Pharmacy, 30(3), 218 - 225. https://doi.org/10.18553/jmcp.2023.23277 picture_as_pdf
  • Hoefer, Carl, Krauss, Alexander (2021). Measures of effectiveness in medical research: reporting both absolute and relative measures. Studies in history and philosophy of science, 88, 280 - 283. https://doi.org/10.1016/j.shpsa.2021.06.012 picture_as_pdf
  • Hong, Jihyung, Reed, Catherine, Novick, Diego, Haro, Josep Maria, Aguado, Jaume (2011). Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study. Psychiatry Research, 190(1), 110-114. https://doi.org/10.1016/j.psychres.2011.04.016
  • Howard, Robert, McShane, Rupert, Lindesay, James, Ritchie, Craig, Baldwin, Ashley, Barber, Robert, Burns, Alistair, Dening, Tom, Findlay, David & Holmes, Clive et al (2015). Nursing home placement in the Donepezil and Memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology, 14(12), 1171-1181. https://doi.org/10.1016/S1474-4422(15)00258-6
  • Ikeda, S., Ikegami, N., Oliver, Adam, Ikeda, M. (1996). A case for the adoption of pharmacoeconomic guidelines in Japan. PharmacoEconomics, 10, 546-551.
  • Izmirlieva, Milena (2025). Application of international reference pricing rules to forecast pharmaceutical launch prices in 5 European countries. Value in Health, 29(1), 173-181. https://doi.org/10.1016/j.jval.2025.08.003
  • Jackson, N., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H. & Janmohamed, S. et al (2015). Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, https://doi.org/10.1093/eurheartj/ehv213
  • Jackson, Emily, Feldschreiber, P, Breckenridge, A (2017). Regulatory consequences of “Brexit” for the development of medicinal products. Clinical Pharmacology and Therapeutics, 102, 183-184. https://doi.org/10.1002/cpt.706
  • Jaffray, Mariesha, Bond, Christine M., Watson, M. C., Hannaford, Philip, Tinelli, Michela, Scott, A., Lee, A., Blenkinsopp, Alison, Anderson, Cameron & Avery, Anthony et al (2007). The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Family Practice, 24(2), 189-200. https://doi.org/10.1093/fampra/cml075
  • Jiménez Rubio, Dolores, Hernández-Quevedo, Cristina (2010). Spain: the effect of country of birth on patterns of pharmaceutical use. Eurohealth, 16(4), 18-19.
  • Kamphuis, Bregtje W., Kanavos, Panos (2021). Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy OPEN, 2, https://doi.org/10.1016/j.hpopen.2021.100045 picture_as_pdf
  • Kanavos, Panos (1999). Financing pharmaceuticals in transition. Croatian Medical Journal, 40(June), 244-259.
  • Kanavos, Panos, Angelis, Aris, Drummond, Michael (2019). An EU-wide approach to HTA an irrelevant development or an opportunity not to be missed? European Journal of Health Economics, 20(3), 329-332. https://doi.org/10.1007/s10198-019-01037-2
  • Kanavos, Panos, Mossialos, Elias (1999). Outstanding regulatory issues in the European Union pharmaceutical market. PharmacoEconomics, 15(6), 519-533.
  • Kanavos, Panos, Nicod, Elena (2012). What is wrong with orphan drug policies?: suggestions for ways forward. Value in Health, 15(8), 1182-1184. https://doi.org/10.1016/j.jval.2012.08.2202
  • Kanavos, Panos, Angelis, Aris (2014). Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1? Pharmaceutical Medicine, online, https://doi.org/10.1007/s40290-014-0066-2
  • Kanavos, Panos, Kamphuis, Bregtje W., Fontrier, Anna-Maria, Parkin, Georgia Colville, Saleh, Shadi, Akhras, Kasey S. (2020). Pricing of in-patent pharmaceuticals in the Middle East and North Africa is external reference pricing implemented optimally? Health Policy, 124(12), 1297 - 1309. https://doi.org/10.1016/j.healthpol.2020.07.017 picture_as_pdf
  • Kanavos, Panos, Vandoros, Sotiris (2011). Determinants of branded prescription medicine prices in OECD countries. Health Economics, Policy and Law, 6(3), 1-31. https://doi.org/10.1017/S1744133111000090
  • Kawalec, Paweł, Sagan, Anna, Pilc, Andrzej (2016). The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Orphanet Journal of Rare Diseases, 11(122). https://doi.org/10.1186/s13023-016-0501-4
  • Kravdal, Øystein, Grundy, Emily, Skirbekk, Vegard (2017). Fertility history and use of antidepressant medication in late mid-life: a register-based analysis of Norwegian women and men. Aging and Mental Health, 21(5), 477-486. https://doi.org/10.1080/13607863.2015.1118010
  • Lagarde, Mylène, Blaauw, Duane (2023). Levels and determinants of over-prescribing of antibiotics in the public and private primary care sectors in South Africa. BMJ Global Health, 8(7). https://doi.org/10.1136/bmjgh-2023-012374 picture_as_pdf
  • Latonen, S., Neuvonen, E., Juppo, A. M., Seeck, Hannele, Airaksinen, M. (2024). Crisis management in community pharmacies during a pandemic. Research in Social and Administrative Pharmacy, 20(9), 940 - 948. https://doi.org/10.1016/j.sapharm.2024.06.010 picture_as_pdf
  • Latonen, S., Pussila, S., Seeck, Hannele, Airaksinen, M., Juppo, A. M. (2025). Crisis management in the pharmaceutical industry during the COVID-19 pandemic. International Journal of Disaster Risk Reduction, 125, https://doi.org/10.1016/j.ijdrr.2025.105566 picture_as_pdf
  • Levitan, Bennett, Phillips, Lawrence D., Walker, Stuart (2014). Structured approaches to benefit-risk assessment: a case study and the patient perspective. Therapeutic Innovation and Regulatory Science, 48(5), 564-573. https://doi.org/10.1177/2168479014536500
  • Lewer, D., O'Reilly, C., Mojtabai, R., Evans-Lacko, S. (2015). Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. British Journal of Psychiatry, 207(3), 221-226. https://doi.org/10.1192/bjp.bp.114.156786
  • Liebenau, Jonathan (2013). Modernising the business of health: pharmaceuticals in Britain, in comparison with Germany and the United States, 1890-1940. Industrial and Corporate Change, 22(3), 807-847. https://doi.org/10.1093/icc/dtt010
  • Luciano, Juan V., D’Amico, Francesco, Cerdà-Lafont, Marta, Peñarrubia-María, María T., Knapp, Martin, Cuesta-Vargas, Antonio I., Serrano-Blanco, Antoni, García-Campayo, Javier (2014). Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Research and Therapy, 16(5), p. 451. https://doi.org/10.1186/s13075-014-0451-y
  • Luyten, Jeroen, Beutels, Philippe (2009). Costing infectious disease outbreaks for economic evaluation. PharmacoEconomics, 27(5), 379-389. https://doi.org/10.2165/00019053-200927050-00003
  • Luyten, Jeroen, Desmet, Pieter, Dorgali, Veronica, Hens, Niel, Beutels, Philippe (2014). Kicking against the pricks: vaccine sceptics have a different social orientation. European Journal of Public Health, 24(2), 310-314. https://doi.org/10.1093/eurpub/ckt080
  • Luyten, Jeroen, Dorgali, Veronica, Hens, Niel, Beutels, Philippe (2013). Public preferences over efficiency, equity and autonomy in vaccination policy: an empirical study. Social Science & Medicine, 77, 84-89. https://doi.org/10.1016/j.socscimed.2012.11.009
  • Luyten, Jeroen, Marais, Christiaan, Hens, Niel, De Schrijver, Koen, Beutels, Philippe (2011). Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis A patients. Value in Health, 14(2), 282-290. https://doi.org/10.1016/j.jval.2010.10.004
  • Luyten, Jeroen, Van de Sande, Stefaan, De Schrijver, Koen, Van Damme, Pierre, Beutels, Philippe (2012). Cost-effectiveness of hepatitis A vaccination for adults in Belgium. Vaccine, 30(42), 6070-6080. https://doi.org/10.1016/j.vaccine.2012.07.049
  • Luyten, Jeroen, Vandevelde, Antoon, Van Damme, Pierre, Beutels, Philippe (2011). Vaccination policy and ethical challenges posed by herd immunity, suboptimal uptake and subgroup targeting. Public Health Ethics, 4(3), 280-291. https://doi.org/10.1093/phe/phr032
  • Manfrin, Andrea, Knapp, Martin, Cicchetti, Americo, Mandelli, Andrea, Tinelli, Michela (2018). VP164 Applying health technology assessment to pharmacy: the Italian-Medicine-Use-Review-Health Technology Assessment. International Journal of Technology Assessment in Health Care, 33(S1). https://doi.org/10.1017/S0266462317004007
  • Massard da Fonseca, Elize, Shadlen, Kenneth C. (2025). Aligning health, industry, and innovation through public procurement. European Journal of Public Health, picture_as_pdf
  • Maynou-Pujolras, Laia, Cairns, John (2015). Why do some countries approve a cancer drug and others don't? Journal of Cancer Policy, 4, 21-25. https://doi.org/10.1016/j.jcpo.2015.05.004
  • Mehta, Reena, Onatade, Raliat, Vlachos, Savvas, Sloss, Rhona, Maharaj, Ritesh (2023). The association of a critical care electronic prescribing system with the quality of patient care provided by clinical pharmacists - a prospective, observational cohort study. International Journal of Medical Informatics, 177, https://doi.org/10.1016/j.ijmedinf.2023.105119 picture_as_pdf
  • Mercadante Santino De Oliveira, Eduardo, Minssen, Timo, Shadlen, Kenneth C., van Zimmeren, Esther, Zemła-Pacud, Żaneta, Matthews, Duncan (2025). A global landscape of patenting activity in COVID-19 vaccines. Vaccine, 67, https://doi.org/10.1016/j.vaccine.2025.127866 picture_as_pdf
  • Mercadante, Eduardo, Paranhos, Julia (2022). Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018). Cadernos de saude publica, 38(1). https://doi.org/10.1590/0102-311X00043021 picture_as_pdf
  • Michaeli, Daniel Tobias, Mills, Mackenzie, Michaeli, Thomas, Miracolo, Aurelio, Kanavos, Panos (2022). Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Investigational New Drugs, 40(4), 798 - 809. https://doi.org/10.1007/s10637-022-01227-5 picture_as_pdf
  • Mossialos, Elias, Courtin, Emilie, Naci, Huseyin, Benrimoj, Shalom, Bouvy, Marcel, Farris, Karen, Noyce, Peter, Sketris, Ingrid (2015). From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy, 119(5), 628-639. https://doi.org/10.1016/j.healthpol.2015.02.007 picture_as_pdf
  • Mt-Isa, Shahrul, Hallgreen, Christine E., Wang, Nan, Callréus, Torbjörn, Genov, Georgy, Hirsch, Ian, Hobbiger, Stephen F., Hockley, Kimberley S., Luciani, Davide & Phillips, Lawrence D. et al (2014). Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiology and Drug Safety, 23(7), 667-678. https://doi.org/10.1002/pds.3636
  • Mwita, Stanley, Jande, Mary, Marwa, Karol, Hamasaki, Kayo, Katabalo, Deogratius, Burger, Johanita, Godman, Brian, Ferrario, Alessandra, Massele, Amos, Ruganuza, Deodatus (2017). Medicines dispensers' knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. Journal of Pharmaceutical Health Services Research, https://doi.org/10.1111/jphs.12187
  • Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Double failure: the shared accountability of governments and firms for the innovation deficit in the pharmaceutical sector. BMJ, picture_as_pdf
  • Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Why the drug development pipeline is not delivering better medicines. BMJ, 351, https://doi.org/10.1136/bmj.h5542
  • Naci, Huseyin, Kesselheim, Aaron S. (2020). Specialty drugs: a distinctly American phenomenon. New England Journal of Medicine, 382(23), 2179 - 2181. https://doi.org/10.1056/NEJMp1909513 picture_as_pdf
  • Naci, Huseyin, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Dr.rer.nat, Beate Wiesler, Rochaix, Lise, Redberg, Rita, Salanti, Georgia, Jackson, Emily, Garner, Sarah & Stroup, Scott et al (2020). Generating comparative evidence on new drugs and devices before approval. The Lancet, 395(10228), 986 - 997. https://doi.org/10.1016/S0140-6736(19)33178-2 picture_as_pdf
  • Naci, Huseyin, Wouters, Olivier J., Gupta, Radhika, Ioannidis, John P. A. (2017). Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. The Milbank Quarterly, 95(2), 261 - 290. https://doi.org/10.1111/1468-0009.12261
  • Nicod, Elena, Annemans, Lieven, Bucsics, Anna, Lee, Anne, Upadhyaya, Sheela, Facey, Karen (2017). HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries. Health Policy, https://doi.org/10.1016/j.healthpol.2017.03.009
  • Oliver, Adam, Ikegami, N., Ikeda, S. (1999). The Japanese government's pharmaceutical policy and its effect on hospital financial viability. Journal of Health Services Research and Policy, 4, 27-32.
  • Pan, Yi-Ju, Knapp, Martin, McCrone, Paul R. (2012). Cost-effectiveness comparisons between antidepressant treatments in depression: evidence from database analyses and prospective studies. Journal of Affective Disorders, 139(2), 113-125. https://doi.org/10.1016/j.jad.2011.07.020
  • Phillips, Lawrence D., Fasolo, Barbara, Zafiropoulos, Nikolaos, Beyer, Andrea (2011). Is quantitative benefit–risk modelling of drugs desirable or possible? Drug Discovery Today: Technologies, 8(1), e3-e10. https://doi.org/10.1016/j.ddtec.2011.03.001
  • Renwick, Mathew, Mossialos, Elias (2018). What are the economic barriers of antibiotic R&D and how can we overcome them? Expert Opinion on Drug Discovery, 13(10), 889-892. https://doi.org/10.1080/17460441.2018.1515908
  • Salas-Vega, Sebastian, Bertling, Annika, Mossialos, Elias (2016). A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 120(10), 1104-1114. https://doi.org/10.1016/j.healthpol.2016.08.006
  • Salas-Vega, Sebastian, Shearer, Emily, Mossialos, Elias (2020). Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Social Science & Medicine, 258, https://doi.org/10.1016/j.socscimed.2020.113042 picture_as_pdf
  • Salcher-Konrad, Maximilian, Naci, Huseyin, Davis, Courtney (2020). Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Quarterly, 98(4), 1219 - 1256. https://doi.org/10.1111/1468-0009.12476 picture_as_pdf
  • Sampat, Bhaven N., Shadlen, Kenneth C., Amin, Tahir M. (2012). Challenges to India's pharmaceutical patent laws. Science, 337(6093), 414-415. https://doi.org/10.1126/science.1224892
  • Sampat, Bhaven N., Shadlen, Kenneth C. (2015). Drug patenting in India: looking back andlooking forward. Nature Reviews: Drug Discovery, 14, 519-520. https://doi.org/10.1038/nrd4681
  • Santos, Carolina, Costa, Eduardo, Machado, Sara (2025). The impact of multimarket competition on generic drugs' regulated prices. Health Economics, 34(12), 2196 - 2222. https://doi.org/10.1002/hec.70029
  • Schlag, Anne Katrin, Baldwin, David S., Barnes, Michael, Bazire, Steve, Coathup, Rachel, Curran, H. Valerie, McShane, Rupert, Phillips, Lawrence D., Singh, Ilina, Nutt, David J. (2020). Medical cannabis in the UK: from principle to practice. Journal of Psychopharmacology, 34(9), 931 - 937. https://doi.org/10.1177/0269881120926677 picture_as_pdf
  • Serra-Sastre, Victoria, McGuire, Alistair (2013). Information and diffusion of new prescription drugs. Applied Economics, 45(15), 2049-2057. https://doi.org/10.1080/00036846.2011.648321
  • Shadlen, Kenneth C. (2011). The political contradictions of incremental innovation: lessons from pharmaceutical patent examination in Brazil. Politics & Society, 39(2), 143-174. https://doi.org/10.1177/0032329211402601
  • Shadlen, Kenneth C., Sampat, Bhaven N. (2018). Indian pharmaceutical patent prosecution: the changing role of Section 3(d). PLOS ONE, 13(4). https://doi.org/10.1371/journal.pone.0194714
  • Shadlen, Kenneth C., Sampat, Bhaven N., Kapczynski, Amy (2020). Patents, trade, and medicines: past, present, and future. Review of International Political Economy, 27(1), 75 - 97. https://doi.org/10.1080/09692290.2019.1624295 picture_as_pdf
  • Shahzad, Mahnum, Naci, Huseyin, Wagner, Anita K. (2023). Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. JAMA, 329(9), 760 - 761. https://doi.org/10.1001/jama.2023.0625
  • Simpkin, Victoria, Namubiru-Mwaura, Evelyn, Clarke, Lorcan, Mossialos, Elias (2019). Investing in health R&D: where we are, what limits us, and how to make progress in Africa. BMJ Global Health, 4(2). https://doi.org/10.1136/bmjgh-2018-001047 picture_as_pdf
  • Sosa, M. Lourdes (2009). Application-specific R&D capabilities and the advantage of incumbents: evidence from the anticancer drug market. Management Science, 55(8), 1409-1422. https://doi.org/10.1287/mnsc.1090.1027
  • Sosa, M. Lourdes (2013). Decoupling market incumbency from organizational prehistory: locating the real sources of competitive advantage in R&D for radical innovation. Strategic Management Journal, 34(2), 245-255. https://doi.org/10.1002/smj.2012
  • Srivastava, Divya, McGuire, Alistair (2014). Analysis of prices paid by low-income countries: how price sensitive is government demand for medicines? BMC Public Health, 14(1), p. 767. https://doi.org/10.1186/1471-2458-14-767
  • Stoneman, Paul, Sturgis, Patrick, Allum, Nick (2013). Understanding support for complementary and alternative medicine in general populations: Use and perceived efficacy. Health (United Kingdom), 17(5), 512-529. https://doi.org/10.1177/1363459312465973
  • Sullivan, Sean D., Grueger, Jens, Sullivan, Aidan P., Ramsey, Scott D. (2025). The consequences of pharmaceutical tariffs in the United States. Journal of Managed Care & Specialty Pharmacy, 31(6), 533 - 536. https://doi.org/10.18553/jmcp.2025.25090
  • Sullivan, Sean D., Wouters, Olivier J., Cousin, Emma M., Kirihennedige, Ayuri S., Hernandez, Inmaculada (2024). Integrating price benchmarks and comparative clinical effectiveness to inform the medicare drug price negotiation program. Value in Health, 27(10), 1348 - 1357. https://doi.org/10.1016/j.jval.2024.08.001 picture_as_pdf
  • Thambisetty, Sivaramjani (2014). Novartis v Union of India and the person skilled in the art: a missed opportunity. Queen Mary Journal of Intellectual Property, 4(1), 79-94. https://doi.org/10.4337/qmjip.2014.01.04
  • Thambisetty, Sivaramjani (2019). Improving access to patented medicines are human rights getting in the way? Intellectual Property Quarterly, 4, 284-305. picture_as_pdf
  • Tinelli, Michela (2017). Better outcomes for the patient, the provider and the society now: this is not a dream, and the pharmacist could help! BMJ,
  • Tinelli, Michela (2002). Costi dell’aterosclerosi. Farmacoeconomia News, 2, 27-51.
  • Tinelli, Michela (2002). Neuropatie diabetiche ed L-carnitina: nuove prospettive di trattamento. Farmacoeconomia News, 3,
  • Tinelli, Michela, Blenkinsopp, Alison, Latter, Sue, Smith, Alesha, Chapman, Stephen R. (2015). Survey of patients' experiences and perceptions of care provided by nurse and pharmacist independent prescribers in primary care. Health Expectations, 18(5), 1241-1255. https://doi.org/10.1111/hex.12099
  • Tinelli, Michela, Jaffray, M, Krksa, J., Bond, Christine M. (2007). The MEDMAN project: evaluation of the medicines management training for community pharmacists. Pharmacy Education, 7(3), 207-214.
  • Tinelli, Michela, Ryan, M., Bond, Christine (2007). Economic evaluation advancement in pharmacy: discrete choice experiments (DCEs). International Journal of Pharmacy Practice, 15(s1). https://doi.org/10.1211/096176707781607143
  • Tinelli, Michela, Ryan, M., Bond, Christine (2010). Session 1A: methods. Discrete choice experiments (DCEs) to inform pharmacy policy: going beyond Quality Adjusted Life Years (QALYs). International Journal of Pharmacy Practice, 18 (S), 1-4. https://doi.org/10.1111/j.2042-7174.2010.00001.x
  • Tinelli, Michela, Ryan, Mandy, Bond, Christine (2006). Patient-centred approach to policy development: a pharmacy-led medicines management service. International Journal of Pharmacy Practice, 14 (S), 71-72.
  • Tinelli, Michela, White, John, Manfrin, Andrea (2018). Novel pharmacist-led intervention secures the minimally important difference (MID) in Asthma Control Test (ACT) score: better outcomes for patients and the healthcare provider. BMJ Open Respiratory Research, 5(1), e000322. https://doi.org/10.1136/bmjresp-2018-000322 picture_as_pdf
  • Vandoros, Sotiris, Kanavos, Panos (2014). Parallel trade and pharmaceutical prices: a game-theoretic approach and empirical evidence from the European Union. World Economy, 37(6), 856-880. https://doi.org/10.1111/twec.12063
  • Vogler, Sabine, Zimmermann, Nina, Ferrario, Alessandra, Wirtz, Veronika J, Babar, Zaheer-Ud-Din (2015). Challenges and opportunities for pharmaceutical pricing and reimbursement policies. Journal of Pharmaceutical Policy and Practice, 8(Suppl). https://doi.org/10.1186/2052-3211-8-S1-E1
  • Von der Schulenburg, Fritz, Vandoros, Sotiris, Kanavos, Panos (2011). The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Economics Review, 1(1), 1-8. https://doi.org/10.1186/2191-1991-1-18
  • Vreman, Rick A., Naci, Huseyin, Goettsch, Wim G., Mantel-Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G.M., Kesselheim, Aaron S. (2020). Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. https://doi.org/10.1002/cpt.1835 picture_as_pdf
  • Wallis, Patrick (2000). The first English histories of pharmacy - their origins and influences. Pharmacy in History, 42(1), 36-46.
  • Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Guan, Xiaodong (2024). Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45, https://doi.org/10.1016/j.lanwpc.2024.101055 picture_as_pdf
  • Wilson, Leslie, Turkistani, Fatema A., Huang, Wei, Tran, Dang M., Kuo Lin, Tracy (2018). The impact of alternative pricing methods for drugs in California Workers’ Compensation System: fee-schedule pricing. PLOS ONE, 13(5), e0197449. https://doi.org/10.1371/journal.pone.0197449
  • Wouters, Olivier J., Denolle, Cyprien, Wei, Jinru, Papanicolas, Irene (2025). Prices and affordability of essential medicines in 72 low-, middle-, and high-income markets. JAMA Health Forum, 6(8). https://doi.org/10.1001/jamahealthforum.2025.2043 picture_as_pdf
  • Wouters, Olivier J., Kanavos, Panos (2015). Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Bulletin of the World Health Organization, 93(9), 606-613. https://doi.org/10.2471/BLT.14.148742
  • Wouters, Olivier J., Kanavos, Panos (2017). A comparison of generic drug prices in seven European countries: a methodological analysis. BMC Health Services Research, 17(242), 1-7. https://doi.org/10.1186/s12913-017-2184-5
  • Wouters, Olivier J., Kesselheim, Aaron S., Kuha, Jouni, Luyten, Jeroen (2024). Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014: a retrospective study. Value in Health, 27(10), 1373 - 1381. https://doi.org/10.1016/j.jval.2024.06.015 picture_as_pdf
  • Xin, Tangsiwei (2025). Combating substandard and falsified medicines in China: policy barriers and the role of pharmaceutical track-and-trace systems. Critical Public Health, 35(1). https://doi.org/10.1080/09581596.2025.2513645 picture_as_pdf
  • Zafiropoulos, Nikolaos, Phillips, Lawrence D., Pignatti, Francesco, Luria, Xavier (2012). Evaluating benefit-risk: an Agency perspective. Regulatory Rapporteur, 9(6), 5-8.
  • Zaitceva, Viktoriia, Eaves, Kristian, Mills, Mackenzie, Kanavos, Panos (2025). P53 Alignment between CDA recommendations and pCPA negotiation outcomes: exploring factors influencing reimbursement success. Value in Health, 28(6, Supplement 1), S19. https://doi.org/10.1016/j.jval.2025.04.071
  • da Silva Menolli, Poliana Vieira, Brummel, Adriana Mitsue Ivama, Guidoni, Camilo Molino, Girotto, Edmarlon (2024). Patient’s perception of medication and nonadherence to chronic disease treatments. A population-based study in Brazil. Journal of Pharmaceutical Health Services Research, 15(1). https://doi.org/10.1093/jphsr/rmae001 picture_as_pdf
  • van Amsterdam, Jan, Phillips, Lawrence D., Henderson, Graeme, Bell, James, Bowden-Jones, Owen, Hammersley, Richard, Ramsey, John, Taylor, Polly, Dale-Perera, Annette & Melichar, Jan et al (2015). Ranking the harm of non-medically used prescription opioids in the UK. Regulatory Toxicology and Pharmacology, 73(3), 999-1004. https://doi.org/10.1016/j.yrtph.2015.09.014
    • Book
  • Shadlen, Kenneth C., Guennif, Samira, Guzmán, Alenka, Lalitha, N. (Eds.) (2011). Intellectual property, pharmaceuticals and public health: access to drugs in developing countries. Edward Elgar.
    • Chapter
  • Collins, John (2017). Regulation as global drug governance: how new is the NPS phenomenon? In Corazza, Ornella, Roman-Urrestarazu, Andres (Eds.), Novel Psychoactive Substances (pp. 23-41). Springer Berlin / Heidelberg. https://doi.org/10.1007/978-3-319-60600-2_3 picture_as_pdf
  • Permanand, Govin, Altenstetter, Christa (2004). The politics of the EU pharmaceutical industry. In Mossialos, Elias, Mrazek, Monique, Walley, Tom (Eds.), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (pp. 38-54). Open University.
  • Phillips, Lawrence D. (2013). Benefit-risk modeling of medicinal products: methods and applications. In Sashegyi, Andreas, Felli, James, Noel, Rebecca (Eds.), Benefit-Risk Assessment in Pharmaceutical Research and Development (pp. 59-96). CRC Press.
  • Shadlen, Kenneth C. (2011). The politics of patents and drugs in Brazil and Mexico: the industrial bases of health policies. In Shadlen, Kenneth C., Guennif, Samira, Guzmán, Alenka, Lalitha, N. (Eds.), Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries (pp. 178-201). Edward Elgar.
  • Shadlen, Kenneth C., Guennif, Samira, Guzmán, Alenka, Lalitha, N. (2011). Globalization, intellectual property rights, and pharmaceuticals: meeting the challenges to addressing health gaps in the new international environment. In Shadlen, Kenneth C., Guennif, Samira, Guzmán, Alenka, Lalitha, N. (Eds.), Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries (pp. 1-28). Edward Elgar.
    • Conference or Workshop Item
  • Community Pharmacy Medicines Management Evaluation Team (2004-09-27 - 2004-09-29) Community pharmacists’ attitudes and knowledge of medicines management [Other]. British Pharmaceutical Conference, Manchester, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Project Evaluation Team (2005-01-01) Community pharmacists’ perceptions and experiences of interprofessional collaboration with general practitioners [Other]. Health Services Research and Pharmacy Practice Conference, Reading, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Project Evaluation Team (2005-01-01) Evaluating patient feedback on a new medicines management service provided by community pharmacists [Other]. Health Services Research and Pharmacy Practice Conference, Reading, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Evaluation Team (2004-09-27 - 2004-09-29) Evaluation of the Community Pharmacy Medicines Management Project [Other]. British Pharmaceutical Conference, Manchester, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Evaluation Team (2005-01-01) General Practitioners’ opinions of and attitudes towards a community pharmacist-led medicines management service for patients with coronary heart disease [Other]. Society for Academic Primary Care AGM, Newcastle, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Project Evaluation Team (2005-01-01) General Practitioners’ perceptions of interprofessional collaboration with community pharmacists [Other]. Health Services Research and Pharmacy Practice Conference, Reading, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Evaluation Team (2005-01-01) Practice staff’s views on a community pharmacy-led medicines management service [Other]. Health Services Research and Pharmacy Practice Conference, Reading, United Kingdom, GBR.
  • Community Pharmacy Medicines Management Evaluation Team (2005-01-01) What patients want from a pharmacy-led medicines management service [Other]. Health Services Research and Pharmacy Practice Conference, Reading, United Kingdom, GBR.
  • Cordella, Antonio (2002-05-09 - 2002-05-11) Knowledge production vs knowledge management: the case of pharmaceutical R&D [Paper]. EURAM 2nd Annual Conference: Innovative Research in Management, Stockholm, Sweden, SWE.
  • Cordella, Antonio, Grisot, M. (2002-05-09 - 2002-05-11) Distributed knowledge across boundaries [Paper]. EURAM 2nd Annual Conference: Innovative Research in Management, Stockholm, Sweden, SWE.
  • Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Competition issues in the distribution of pharmaceuticals [Paper]. OECD Global Forum on Competition, Paris, France, FRA.
  • Kanavos, Panos, Wouters, Olivier J. (2014-02-27 - 2014-02-28) Concurrence dans la distribution de produits pharmaceutiques [Paper]. OECD Forum Mondial sur la Concurrence, Paris, France, FRA.
  • Matheson, Catriona, Bond, C., Tinelli, Michela (2006-09-04 - 2006-09-06) Community pharmacists and drug misusers: national trends in attitudes and current practice [Other]. British Pharmaceutical Conference, Manchester, United Kingdom, GBR.
  • Tinelli, Michela, Manfrin, Andrea, Knapp, Martin, Mandelli, A. (2017-06-17 - 2017-06-21) VP164: Applying HTA to pharmacy: the Italian-Medicine-Use-Review-HTA [Paper]. HTAi 2017 Annual Meeting, Rome, Italy, ITA.
    • Report
  • European Medicines Agency (2014). Benefit-risk methodology project:update on work package 5: effects table pilot (phase I). European Medicines Agency.
  • European Medicines Agency (2011). Benefit-risk methodology project:work package 1 report: description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network. European Medicines Agency.
  • European Medicines Agency (2011). Benefit-risk methodology project:work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment. European Medicines Agency.
  • European Medicines Agency (2011). Benefit-risk methodology project:work package 3 report: field tests. European Medicines Agency.
  • European Medicines Agency (2012). Benefit-risk methodology project:work package 4 report: benefit-risk tools and processes. European Medicines Agency.
  • Medical Technology Research Group – LSE Health London School of Economics and Political Science (2011). Differences in costs of and access to pharmaceutical products in the EU. European Parliament.
  • Alkazemi, Mariam (2018). Regulation of healthcare advertisements: comparing media regulation of the pharmaceutical industry in Kuwait and the GCC. (LSE Middle East Centre papers series 23). LSE Middle East Centre.
  • Beutels, Philippe, Luyten, Jeroen, Lejeune, Olivier, Hens, Niel, Bilcke, Joke, De Schrijver, Koen, Van de Sande, Stefaan, Van Herck, Koen, Van Damme, Pierre (2008). Evaluatie van universele en doelgroep hepatitis A vaccinatie opties in België = Evaluation of universal and targeted hepatitis A vaccination programs in Belgium. (KCE reports 98A (D/2008/10.273/88)). Federaal Kenniscentrum voor de Gezondheidszorg (KCE).
  • Bonser, Andrew, Kanavos, Panos, Taylor, David (2016). Tender Loving Care? Purchasing medicines for continuing therapeutic improvement and better health outcomes. London School of Economics and Political Science.
  • Ferrario, Alessandra, Kanavos, Panos (2013). Managed entry agreements for pharmaceuticals: the European experience. EMiNet.
  • Hibberd, Ralph, Barber, Nick, Cornford, Tony, Lichtner, Valentina (2012). The evaluation of the electronic prescription service in primary care: interim report on the findings from the evaluation in early implementer sites. University College London.
  • Hughes, Diana, Waddingham, Ed, A., J., Mt-Isa, Shahrul, Goginsky, Alesia, Chan, Edmond, Downey, Gerald, Hallgreen, Christine E., Hockley, Kimberley S., Juhaeri, Juhaeri & Lieftucht, Alfons et al (2014). IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines. PROTECT Consortium.
  • Jaffray, Mariesha, Bond, Christine, Tinelli, Michela (2005). The Community Pharmacy Medicines Management Project: final report. University of Aderdeen, Keele University, University of Nottingham, The College of Pharmacy Practice.
  • Kanavos, Panos, Vandoros, Sotiris, Irwin, Rachel, Nicod, Elena, Casson, Margaret (2010). The European pharmaceutical market and policies - outlook for the future. European Parliament.
  • Micaleff, Alain, Callreus, Tornbjorn, Phillips, Lawrence D., Hughes, Diana, Hockley, Kimberley, Wang, Nan, Luciani, David (2013). IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab). PROTECT Consortium.
  • Mossialos, Elias, Kanavos, Panos, Abel-Smith, B. (1994). Policy options for pharmaceutical research and development in the European Community. (Science and Technology Options Assessment Programme). European Parliament.
  • Mossialos, Elias, Mrazek, Monique F. (2003). The regulation of pharmacies in six countries: report prepared for the Office of Fair Trading. Office of Fair Trading.
  • Mossialos, Elias, Srivastava, Divya (2008). Pharmaceutical policies in Finland - challenges and opportunities. (Observatory Studies Series 10). World Health Organization.
  • Mt-Isa, Shahrul, Hallgreen, Christine, E., Asiimwe, Alex, Downey, Gerry, Genov, Georgy, Hermann, Richard, Hughes, Diana, Lieftucht, Alfons, Noel, Rebecca & Peters, Ruth et al (2013). Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: stage 2 of 2. PROTECT Consortium.
  • Mt-Isa, Shahrul, Peters, Ruth, Phillips, Lawrence D., Chan, Kakit, Hockley, Kimberley S., Wang, Nan, Ashby, Deborah, Tzoulak, Ioanna (2013). Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: Stage 1 of 2. PROTECT Consortium.
  • Phillips, Lawrence D., Amzal, Billy, Asiimwe, Alex, Chan, Edmond, Chen, Chen, Hughes, Diana, Juhaeri, Juhaeri, Micaleff, Alain, Mt-Isa, Shahrul & Noel, Becky et al (2013). IMI work package 5: report 2:b:ii benefit - riskwave 2 case study report: Rosiglitazone. PROTECT Consortium.
    • Thesis
  • Tinelli, Michela (2007). Developing and applying discrete choice experiments (DCEs) to inform pharmacy policy [Doctoral thesis]. University of Aberdeen.
    • Online resource
  • Angelis, Aris (2016). Why are the prices of new medicines so high and what can we do about it? (F8).
  • Beckett, Charlie (2007). MMR, the media and risk.
  • Cohen, Lucía (2013). Pharma online: does regulation or corporate social media policy need to change to allow a real dialogue about medicines?
  • Cornford, Tony (2017). The digital future beyond the pill.
  • Costa-Font, Joan, Rudisill, Caroline, Stefanie, Tan (2014). How important is patient brand loyalty in the uptake of generic drugs?
  • Costa-i-Font, Joan (2015). Parallel trade in medicinal drugs is putting the welfare of EU patients at risk.
  • Coulter, Steve (2014). The war over drugs: what’s at stake?
  • Dickson, Jane (2016). $1 million for a drug used once.
  • Dickson, Jane (2015). 165,000 and counting!
  • Dickson, Jane (2015). Books about the future of medicine, digital doctors, patient safety etc.
  • Dickson, Jane (2015). D3 Research presents a poster at the LSE Research Festival.
  • Dickson, Jane (2014). The D3 project.
  • Dickson, Jane (2015). Digital necklace wins Unicef award.
  • Dickson, Jane (2015). E-prescribing and ADE in primary care – data and evidence from meaningful use in the US.
  • Dickson, Jane (2015). Enduring and emerging challenges of informed consent.
  • Dickson, Jane (2015). Mental health monitoring through ‘selfie’ videos and social media tracking.
  • Dickson, Jane (2015). NHS England initiative: ‘combinatorial innovation’ in NHS test beds.
  • Dickson, Jane (2015). National systems of patient unique identifiers – nations pro and against.
  • Dickson, Jane (2015). Non-adherence to prescriptions is categorical construct. Non-persistence adds a time dimension to it.
  • Dickson, Jane (2015). Personalized medicine: a podcast.
  • Dickson, Jane (2014). Pharmacogenetics test lab embedded in ePrescribing, for personalised medicine?
  • Dickson, Jane (2015). Precision medicine on BBC Radio 4 Today Programme.
  • Dickson, Jane (2014). Research hypothesis and objectives.
  • Dickson, Jane (2015). Results of latest international action on counterfeit and unlicensed medicines.
  • Dickson, Jane (2015). Serialisation of individual pills to defeat counterfeiters.
  • Dickson, Jane (2016). Shining a light on Lumosity’s claims.
  • Dickson, Jane (2015). Sounds like a diagnosis?
  • Dickson, Jane (2015). Stratified medicine in 2015 – Leeds Christmas lecture.
  • Dickson, Jane (2015). Tackling the problem of sub-standard therapeutic drugs in Kenya.
  • Dickson, Jane (2016). Testing & mental health apps.
  • Dickson, Jane (2015). Type 1 diabetes breakthrough.
  • Dickson, Jane (2016). Vita brevis ars longa: feeding Watson on dubious data.
  • Dickson, Jane (2017). Vocal biomarkers: diagnostics through human voice.
  • Dickson, Jane (2017). Warfarin history timeline.
  • Dickson, Jane (2015). Worrying about data.
  • Dickson, Jane (2015). A decision support tool for warfarin prescribing.
  • Duffin, Tony (2018). How academics and service providers are working together to inform drug policy in Ireland.
  • Dyke, Heather (2016). Why is doping wrong anyway?
  • Evans-Lacko, Sara, Knapp, Martin (2016). Cost of depression in the workplace across eight diverse countries – collectively US$250 billion.
  • Hibberd, Ralph (2016). Accelerating access to new drugs in Japan.
  • Hibberd, Ralph (2017). Brexit and the falsified medicines directive.
  • Hibberd, Ralph (2016). Combating falsified medicines in Africa through digital artefacts.
  • Hibberd, Ralph (2016). Hub and spoke dispensing: privacy and sociotechnical rigidity.
  • Hibberd, Ralph (2016). Hub and spoke dispensing: safety and sociotechnical pliability.
  • Lichtner, Valentina (2016). ‘the little liar’ – patient information about medicines.
  • Morais de Oliveira, Iago (2016). Using international human rights law to guarantee the right to health: a Brazilian experience.
  • Mossialos, Elias, Ge, Yanfeng, Hu, Jia, Wang, Liejun (2016). Building a strong pharmaceutical system for China.
  • Olczak, Kaya, Salcher, Maximillian, Naci, Huseyin (2016). What works best in congenital heart disease? Comparing two interventions for treatment of Aortic Coarctation.
  • Relle, Katherine (2013). Why social media is good for medicine and why pharmaceutical companies should engage online.
  • Renewick, Matthew, Simpkin, Victoria, Mossialos, Elias (2016). Targeting innovation in antibiotics.
  • Shadlen, Kenneth C. (2016). Debating Patents and Drug Prices: Trade Agreements and the Trans-Pacific Partnership.
  • Shadlen, Kenneth C. (2013). Learning from India? A new approach to secondary pharmaceutical patents. picture_as_pdf
  • Shadlen, Kenneth C., Sampat, Bhaven N., Amin, Tahir M. (2012). Balancing innovation and access: India’s pharmaceutical patent laws. picture_as_pdf
  • Thambisetty, Sivaramjani (2013). Compulsory licenses for pharmaceuticals: an inconvenient truth?
  • Vazza, Lucilla (2016). In Italy primary care prescriptions all electronic from 1 March 2016.
  • Williams, Thomas Christie (2017). Long read review: drug dealer, MD: how doctors were duped, patients got hooked and why it’s so hard to stop by Anna Lembke.
    • Working paper
  • Cockburn, Iain, Lanjouw, Jean O., Schankerman, Mark (2014). Patents and the global diffusion of new drugs. (CEP Discussion Papers CEPDP1298). London School of Economics and Political Science. Centre for Economic Performance.
  • Costa-i-Font, Joan, Hernandez-Quevedo, Christina, Sato, Azusa (2013). A 'Health Kuznets' curve'? Cross-country and longitudinal evidence. (CESifo working paper 4446). CESifo Group.
  • Costa-i-Font, Joan, Varol, Nebibe, McGuire, Alistair (2011). Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008. (CESifo working paper 3441). CESifo Group.
  • Feick, Jürgen (2005). Learning and interest accommodation in policy and institutional change: EC risk regulation in the pharmaceuticals sector. (CARR Discussion Papers DP 25). ESRC Centre for Analysis of Risk and Regulation.
  • Kalbfuß, Jörg, Odermatt, Reto, Stutzer, Alois (2018). Medical marijuana laws and mental health in the United States. (CEP Discussion Papers CEPDP1546). London School of Economics and Political Science. Centre for Economic Performance.
  • Kanavos, Panos (2001). Overview of pharmaceutical pricing and reimbursement regulation. LSE Health.
  • Permanand, Govin, Mossialos, Elias (2004). Theorising the development of the European Union framework for pharmaceutical regulation. LSE Health and Social Care.
  • Thambisetty, Sivaramjani (2018). Improving access to patented medicines: are human rights getting in the way? (LSE Law, Society and Economy Working Papers 3/2018). Department of Law, London School of Economics and Political Science. https://doi.org/10.2139/ssrn.3130703
  • Thambisetty, Sivaramjani (2013). Novartis v Union of India and the person skilled in the art: a missed opportunity. London School of Economics and Political Science ; Social Sciences Research Network.
  • Varol, Nebibe, Costa-i-Font, Joan, McGuire, Alistair (2010). Do international launch strategies of pharmaceutical corporations respond to changes in the regulatory environment? (LSE Health working papers 19/2010). LSE Health, London School of Economics and Political Science.
    • Blog post
  • Ford, Alessandro (7 June 2020) Book review: Enforcing Freedom: Drug Courts, Therapeutic Communities and the Intimacies of the State by Kerwin Kaye. USApp – American Politics and Policy Blog. picture_as_pdf
  • Ford, Alessandro (6 July 2020) Book review: Pills, powder and smoke: inside the bloody war on drugs by Antony Loewenstein. USApp – American Politics and Policy Blog. picture_as_pdf
  • Hannah, A. Lee, Mallinson, Daniel J. (17 July 2020) How the US states have learned from each other to create more comprehensive medical cannabis policies. USApp – American Politics and Policy Blog. picture_as_pdf
  • Pettus, Katherine (11 April 2020) The Covid-19 pandemic means that the running down of US Strategic Stockpile of medicines could not have come at a worse time. USApp-American Politics and Policy Blog. picture_as_pdf
  • Shadlen, Kenneth C., Sampat, Bhaven N. (9 November 2015) Drug patenting in India: looking back and looking forward. South Asia @ LSE. picture_as_pdf
  • Shaked, Yoav (16 December 2021) Big Pharma must embrace the shift to technological solutions in healthcare. LSE Business Review. picture_as_pdf